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The growing importance of human induced pluripotent stem cell-derived cardiomyoyctes
(hiPSC-CMs), as patient-specific and disease-specific models for studying cellular
cardiac electrophysiology or for preliminary cardiotoxicity tests, generated better
understanding of hiPSC-CM biophysical mechanisms and great amount of action
potential and calcium transient data. In this paper, we propose a new hiPSC-CM in silico
model, with particular attention to Ca2+ handling. We used (i) the hiPSC-CM Paci2013
model as starting point, (ii) a new dataset of Ca2+ transient measurements to tune
the parameters of the inward and outward Ca2+ fluxes of sarcoplasmic reticulum, and
(iii) an automatic parameter optimization to fit action potentials and Ca2+ transients.
The Paci2018 model simulates, together with the typical hiPSC-CM spontaneous
action potentials, more refined Ca2+ transients and delayed afterdepolarizations-like
abnormalities, which the old Paci2013 was not able to predict due to its mathematical
formulation. The Paci2018 model was validated against (i) the same current blocking
experiments used to validate the Paci2013 model, and (ii) recently published data about
effects of different extracellular ionic concentrations. In conclusion, we present a new
and more versatile in silico model, which will provide a platform for modeling the effects
of drugs or mutations that affect Ca2+ handling in hiPSC-CMs.
Keywords: human induced pluripotent stem cell-derived cardiomyocyte, action potential, calcium transient,
computer simulation, in silico modeling
INTRODUCTION
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are cardiac cells
derived from stem cells, which have been produced by donor’s differentiated cells by means
of reprogramming (Takahashi et al., 2007). The role of hiPSC-CMs, has become more and
more pervasive in basic electrophysiological studies as well as in applied research, such as
pharmacological tests, since their discover in 2007. As an in vitro human model, hiPSC-CMs
strongly impacted the study of biophysical mechanisms underlying cardiac electrophysiology
at cellular level, both in control and diseased conditions. Especially hiPSC-CMs’ patient- and
Paci et al. hiPSC-CM in Silico Modeling
disease-specificity is fundamental to assess the effects of genetic
mutations, such as Long QT (LQT) (Moretti et al., 2010; Lahti
et al., 2012; Ma et al., 2013), catecholaminergic polymorphic
ventricular tachycardia (CPVT) (Kujala et al., 2012) and
hypertrophic cardiomyopathy (HCM) (Ojala et al., 2016), on
the functionality of cardiomyocytes. Ever since the beginning of
the Comprehensive In vitro Proarrhythmic Assay (CIPA) (http://
cipaproject.org/) in 2013, hiPSC-CMs have had a dramatic
impact on pharmacology, serving as a powerful in vitro model
to test the in silico model predictions regarding cardiac safety or
drug toxicity at cellular level.
During the last 10 years, many progresses were done in
terms of efficiency of hiPSC-CM production and availability
of commercial cell lines. This enabled also the hiPSC-CM
electrophysiological and pharmacological evaluation by means
of medium-throughput (Rajamohan et al., 2016) or even high-
throughput systems (Entcheva and Bub, 2016; Klimas et al.,
2016), where the use of voltage- and calcium-sensitive dyes
has been combined with hiPSC-CM optogenetic stimulation.
Together with the availability of these experimental data, new
methods have been developed to process them (Björk et al., 2017;
Ahola et al., 2018).
The importance of Ca2+ cycling to basic cardiac functionality,
together with the growing availability of hiPSC-CM Ca2+ cycling
data, makes Ca2+ transients, and biomarkers computed onto
them, as interesting as action potential (AP)measurements. Ca2+
is fundamental in the heart excitation-contraction (EC) coupling,
i.e., how the electrical and the mechanical properties of the heart
are linked together and how the AP leads to the cardiomyocyte
contraction. The elements involved in this phenomenon are the
L-type Ca2+ channels, the sarcoplasmic reticulum (SR) and the
sarcomeres, i.e., the contractile unit of the cardiomyocyte. During
the AP upstroke, the L-type Ca2+ channels open and Ca2+
flows into the cardiomyocyte. This Ca2+ influx is sufficient to
trigger the Ca2+ release from SR through the ryanodine-sensitive
Ca2+ channels, which increases the cytosolic Ca2+. Such amount
of Ca2+ allows starting the crossbridge cycle, which is at the
basis of the cardiomyocite contraction and continues until Ca2+
is restored to its basal cytosolic concentration. This is mainly
done by the SERCA-2 pump, which reabsorbs Ca2+ from the
cytosol into the SR. Moreover, cytosolic Ca2+ is extruded into
the extracellular space by the Na+/Ca2+ exchanger (INaCa) and by
the sarcolemmal Ca2+ pump (IpCa). All these mechanisms make
the intracellular Ca2+ concentration change, thus producing
Ca2+ transients associated to the APs (Walker and Spinale, 1999).
In 2013 we published the first in silico hiPSC-CMsmodel (Paci
et al., 2013), based on our previous model of cardiomyocytes
derived from human embryonic stem cells (Paci et al., 2012)
and on the experimental data by Ma et al. (2011). This model
has been widely used for computational studies, such as (i)
the prediction of drug effects on cardiac electrophysiology
(Paci et al., 2015; Lei et al., 2017), (ii) the model extension
to multielectrode array simulations (Raphel et al., 2017), and
(iii) the assessment of hiPSC-CM electrophysiological variability
in control and mutant cells, by means of populations of in
silico hiPSC-CMs (Paci et al., 2017). However, one of the
Paci2013 model limitations resides in its formulations of the
Ca2+ handling system: especially the Ca2+ release from the
sarcoplasmic reticulum (SR) is formulated with the functional
but quite elementary Ca2+ release from the TenTusscher2004
model (ten Tusscher et al., 2004).
In this work, we propose an updated version of the Paci2013
hiPSC-CM ventricular-like model with a more flexible Ca2+
handling formulation. The Ca2+ transients produced by the
model were calibrated on experimental Ca2+ imaging data
recorded in our laboratory on hiPSC-CMs. Moreover, the fine
tuning of the model parameters was performed by means of
an automatic optimization technique (Fabbri et al., 2017), in
order to reproduce realistic AP and Ca2+ transient shapes and
to speed up the parameter tuning phase. Parameter optimization
affected only the parameters representing the Ca2+ SR fluxes
and a very limited set of parameters of membrane currents in
order to be consistent with the voltage clamp experiment fitting
done by Paci et al. (Paci et al., 2013). Finally, the resulting
updated model was validated against ion current blocking
data.
MATERIALS AND METHODS
New Ca2+ Handling System Formulation
The main limitation of the original Paci2013 model (Paci et al.,
2013) and its following minor updates (Paci et al., 2015, 2017)
is the simplified description of the Ca2+ release from SR, i.e., the
release current Irel. Irel was formulated as in the TenTusscher2004
model (ten Tusscher et al., 2004) in the following way:
Irel = Krel ·
(
crel +
arel · Ca
2
SR
b2
rel
+ Ca2SR
)
· d · g
where Krel, arel, brel, and crel are constants, CaSR is the Ca
2+
concentration in the SR reticulum, d is the L-type Ca2+ current
(ICaL) voltage-dependent activation gate, and g is the Irel specific
inactivation gate. Therefore, Irel is not activated by the cytosolic
Ca2+ concentration Cai sensed by the Ryanodine-sensitive
receptor located on the SR membrane, but it is triggered the
same way as ICaL. Due to this mechanism, the model was
not able to produce proarrhythmic triggers, such as delayed
afterdepolarization (DADs) (Fink et al., 2011).
We reformulated Irel according to the formulation used by
Koivumäki et al. (2011) for the human atrial myocyte:
Irel = Irel,max · RyRCaSR · RyRo · RyRc · (CaSR − Cai)
where Irel,max represents the maximum Ca
2+ release from SR,
RyRCaSR is the dependence on CaSR, RyRo is the open (activation)
gating variable, RyRc the closed (inactivation) gating variable. A
third gating variable, RyRa, was used to modulate the working
point (adaptation) of the RyRo and RyRc gates according to the
cytosolic Ca2+ concentration as in Koivumäki et al. (2011). The
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formulation of the single gating variables is the following
RyRCaSR = 1 −
1
1 + e
CaSR − 0.3
0.1
RyRa,ss = RyRa1 −
RyRa2
1+ e
Cai −RyRa,half
RyRa,k
RyRo,ss = 1 −
1
1 + e
Cai − (RyRa +RyRo,half )
RyRo,k
RyRc,ss =
1
1 + e
Cai − (RyRa +RyRc,half )
RyRc,k
where the subscript ss indicates the steady state value of the
gating variable and the subscripts half and k indicate the half
Ca2+ concentration and the slope, respectively, of the gating
variable steady state. The values of the constants RyRa1, RyRa2
and the gating variable half activations RyRa,half , RyRo,half and
RyRc,half were then optimized (together with other parameters)
as described in section “Parameter Optimization.” We report the
full set of equations in section 1 of the Supplementary Material.
The formulation of the other SR fluxes, namely the SERCA
pump (Iup) and the leakage current (Ileak) were not changed
with respect to the Paci2013 model (Paci et al., 2013). However,
their parameters went through the optimization process, as we
describe in section Parameter Optimization. In the following we
will refer as Paci2013 to the model version presented in Paci et al.
(2017).
Parameter Optimization
The parameter optimization process was adapted from Fabbri
et al. (2017).
Shortly, parameter optimization was done using the Matlab©
function fminsearch, which implements the Nelder-Mead
Simplex Method, as reported in Fabbri et al. (2017). Such
function minimizes a cost function built on the experimental
biomarkers we want the model to simulate. The following
equations show the cost function structure (Fabbri et al., 2017):
Cost =
Nbiomarkers∑
i= 1
Costi
Costi =
{
|bi,Exp − bi,Sim|− SDi
SDi
·wi if
∣∣bi,Exp − bi,Sim∣∣ > SD
0 otherwise
whereCosti and SDi represent the cost and the standard deviation
for a single biomarker bi.
The structure of the cost function Cost is consistent with
the cost function used in Fabbri et al. (2017). The contribution
of each biomarker to the overall cost is zero if the biomarker
is within its ±SD range, otherwise it grows linearly. Moreover,
each contribution Costi was weighted according to the respective
weight wi. This results in a non-linear cost function, which is
zero if all the biomarkers are within the experimental ranges and
greater than zero if at least one biomarker is out of range. The AP
experimental biomarkers considered for the cost function were:
AP amplitude (APA), maximum diastolic potential (MDP), cycle
length (CL), maximum upstroke velocity (Vmax), AP duration
at 10, 30, and 90% of repolarization (APD10, APD30, APD90)
and AP shape factor (Triangulation). Triangulation is a shape
factor used by Ma et al. (2011) to discriminate between atrial-like
(Triangulation < 1.5) and ventricular-like (Triangulation>1.5)
APs, and it is computed as:
Triangulation =
APD30 − APD40
APD70 − APD80
The Ca2+ transient experimental biomarkers were: duration
of the Ca2+ transient (DURATION), time to peak (TPEAK),
rise time from 10 to 50% (RT1050), rise time from 10 to
90% (RT1090), decay time from 90 to 10% (DT9010) and the
Ca2+ transient rate (FREQ). The full list of the parameters
optimized by this method and their original values are reported
in Table 1. For optimization, we only chose parameters related
to Ca2+ handling and additional parameters of INaCa and the
Na+/K+ pump (INaK), i.e., those currents for which the Ma
et al. dataset (Ma et al., 2011) did not provide experimental
data. The parameter values were constrained in a range [−20%,
+20%] with respect to their nominal value in the Paci2013model,
in order to avoid non-physiological values, such as negative
conductances. The initial parameter values for RyRa1, RyRa2,
RyRa,half, RyRo,half, RyRc,half were rescaled to 1/10 of their values
in Koivumäki et al. (2011) before the optimization procedure,
in order to adapt them to the Ca2+ concentrations in the
Paci2013 model, and then optimized as the other parameters. All
the other ionic current parameters were kept as in Paci et al.
(2013) and Paci et al. (2017) for the late Na+ current (INaL)
only.
To constrain the model parameters, two different
experimental datasets were used. AP data were taken from
Ma et al. (2011). This is the same dataset used to calibrate
the Paci2013 model and it includes biomarkers computed
on spontaneous ventricular-like hiPSC-CM APs recorded at
35–37◦C. A second, new, dataset was obtained through Ca2+
transient recordings performed at the BioMediTech Institute
(Tampere, Finland).
Calcium Recordings in hiPSC-CMs
This study was carried out in accordance with the
recommendations of Guidelines of the Ethics Committee
of Pirkanmaa Hospital District (Tampere, Finland). The
protocol was approved by the Ethics Committee of Pirkanmaa
Hospital District (Aalto-Setälä R08070). All subjects gave
written informed consent in accordance with the Declaration
of Helsinki. New Ca2+ transient dataset were recorded at
the BioMediTech Institute from healthy control hiPSC-CMs
at 35–37◦C. The generation and characterization of the
control hiPSC line and cardiac differentiation were done as
described earlier (Ojala et al., 2016). Cardiomyocytes plated
on a coverslip were loaded with 4µM Fluo-4 AM (Thermo
Fisher Scientific) for 30min and de-esterified for 10min in
perfusate medium: (in mM) 137 NaCl, 5 KCl, 0.44 KH2PO4, 20
HEPES, 4.2 NaHCO3, 5 D-glucose, 2 CaCl2, 1.2 MgCl2, and 1
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TABLE 1 | Parameters chosen for optimization.
Parameter Description Original
value
Optimized value
Vmax,up (mM/s) Maximum Ca
2+ SERCA
uptake
0.56064 0.5113
Irel,max (mM/s) Maximum Ca
2+ release
current
— 62.5434
RyRa1 (µM) Adaptation gate constant 1 — 0.05354
RyRa2 (µM) Adaptation gate constant 2 — 0.0488
RyRa,half (µM) Activation gate half Ca
2+
concentration
— 0.02427
RyRo,half (µM) Open gate half Ca
2+
concentration
— 0.01042
RyRc,half (µM) Close gate half Ca
2+
concentration
— 0.00144
INaCa,max (pA/pF) Maximum Na
+/Ca2+
exchange current
5.978e3 3917.0463
INaK,max (pA/pF) Maximum Na
+/K+ pump
current
2.2958 2.6351
Kup (mM) SERCA half saturation
constant
2.5e-4 3.1928e-4
Ileak,max (1/s) Maximum Ca
2+ leakage
flux from SR
4.444e-4 4.7279e-4
alpha (-) Factor enhancing outward
nature of INaCa
2.8571432 2.5371
For each parameter we reported its original value as in Paci et al. (2017) and the new
optimized value. We marked those parameters, which were not included in the old version
of the model, as —.
Na-pyruvate dissolved in H2O (all from Sigma Aldrich). pH of
the perfusate medium was adjusted to 7.4 with NaOH (Sigma
Aldrich). Perfusate was heated with an inline heater SH-27B
controlled with a TC-324B controller unit and input into a
RC-25 imaging chamber (all Warner instruments Inc., CT, USA).
Calcium kinetics of spontaneously beating cardiomyocytes
were imaged with an inverted Olympus IX70 microscope
using UApo/340 0,75NA 20x air objective (Olympus, Tokyo,
Japan) and recorded with ANDOR iXon 885 EM-CCD camera
(Andor Technology, Belfast, Northern Ireland) using 2 × 2
binning and synchronized with a Polychrome V light source
by a real time DPS control unit. LiveAcquisition software
(TILL Photonics, Munich, Germany) was used to control light
source and camera during recording. Fluo-4 was excited at
490 nm wavelength and the emission was recorded through
Olympus U-MF2 Alexa 488 band-pass filter cube (ex.470–495,
em.525/50 nm).
Data were recorded from 15 cells for a total of 218 transients.
For each biomarker mean value and standard deviation (SD)
were computed for model calibration. The experimental values
for the biomarkers and their weights are reported in Table 2.
Model Validation With Current Blocker
Simulations
In order to validate the new hiPSC-CM model after the
introduction of the new Irel formulation and the parameters
optimization by means of our Ca2+ transient data, we chose to
TABLE 2 | Experimental and simulated values of the biomarkers considered for
the parameter optimization.
Biomarker Weight in the
cost function
Experimental value
(mean ± SD)
Simulated value
APA (mV) 1 104 ± 6.0 109.6
MDP (mV) 2 −75.6 ± 6.6 −75.8
CL (ms) 2 1700.0 ± 547.7 1549.3
Vmax (V/s) 1 27.8 ± 26.3 24.8
APD10 (ms) 1 74.1 ± 26.3 85.8
APD30 (ms) 1 180 ± 58.6 241.8
APD90 (ms) 1 414.7 ± 119.4 379.8
Triangulation (-) 1 2.5 ± 1.1 3.0
DURATION (ms) 1 804.5 ± 188.0 617.8
TPEAK (ms) 1 270.4 ± 108.3 165.9
RT1050 (ms) 1 82.9 ± 50.5 47.7
RT1090 (ms) 1 167.3 ± 69.8 106.0
DT9010 (ms) 1 409.8 ± 100.1 367.6
FREQ (Hz) 1 0.70 ± 0.38 0.65
Comparison between the simulated biomarkers and the experimental ones used for the
model parameter optimization. AP biomarkers: AP amplitude (APA), maximum diastolic
potential (MDP), cycle length (CL), maximum upstroke velocity (Vmax ), AP duration at 10,
30, and 90% of repolarization (APD10, APD30, APD90 ) and AP shape factor (Triangulation).
Ca2+ transient biomarkers: duration of the transient (DURATION), time to peak (TPEAK),
rise time from 10 to 50% and to 90% (RT1050, RT1090), decay time from 90 to 10% (DT9010)
and the Ca2+ transient rate (FREQ).
replicate the current blocker simulations performed in Paci et al.
(2013). The model was paced at 1Hz for 800 s to reach its steady
state, then the current blocker was simulated by reducing the
maximum conductance of the affected current and finally the
AP biomarkers were computed after 400 s. The current blockers
considered in the simulations were the same used by Ma et al.
(2011): tetrodotoxine (TTX, INa blocker), nifedipine (NIFED,
ICaL blocker), E4031 (IKr blocker) and 3R4S-Chromanol 293B
(CHR, IKs blocker). For TTX, NIFED and E4031 we considered
the following IC50 values: 0.64µM (Ma et al., 2011), 0.038µM
(Ma et al., 2011) and 100 nM (Sanguinetti and Jurkiewicz, 1990;
Gerlach et al., 2010) respectively. In Ma et al. (2011) CHR had
small effects on the AP biomarkers, therefore we tested a range
of block levels: 30, 50, 70, and 90%. The stimulus current was
550 pA for NIFED, E4031 and CHR, while we chose 750 pA
for TTX in order to trigger APs also at the highest blocker
concentrations.
Delayed Afterdepolarizations
In order to trigger DADs in spontaneous APs, Ca2+ overload
had to be simulated: we chose to increase the superfusate
Ca2+ concentration (Volders et al., 2000). To ensure that Ca2+
overload was simulated only once the model was in steady
state, we ran a 800 s simulation without external pacing. From
these steady state conditions, we increased the extracellular
Ca2+ concentration by setting it to 3.945mM and again we
simulated the spontaneous APs. We ran this protocol with both
the Paci2013 and the Paci2018 models.
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RESULTS
Spontaneous Action Potentials and Ca2+
Transients
The automatic optimization process provided a new set of
parameters, which is reported in Table 1, fourth column.
The simulated spontaneous APs and Ca2+ transients were in
agreement with all the biomarker variability ranges (mean ±
SD), as reported in the last column of Table 2. Figure 1 shows
a comparison between the Paci2018 model (in solid blue) and the
Paci2013model (in dashed red). Figure 2 illustrates the simulated
Ca2+ transients and traces from four illustrative cells: the
comparison highlights that the simulated Ca2+ transient contour
is fully in agreement with our experiments. In Figure 3 simulated
spontaneous AP and Ca2+ traces in steady state are reported,
together with the main ionic currents and concentrations. Irel
gating variables, together with the Ca2+ transients, are detailed
in Figure 4. It shows that the Ca2+ release from SR is not directly
dependent on the ICaL activation, but on the cytosolic Ca
2+
concentration Cai, which rules the behavior of the RyRo, RyRc,
and RyRa gating variables.
Current Blocker Simulations
We compared in Table 3 the current blocker effects on the AP
biomarkers (i) experimentally recorded by Ma et al. (2011),
(ii) simulated by means of the Paci2013 model (Paci et al.,
2013), and (iii) simulated by the Paci2018 model. Figure 5
shows that, despite the changes in the Irel formulation and
parameter optimization, the behavior of the Paci2018 model is
still consistent with the Paci2013 simulations (Paci et al., 2013)
and the experimental data by Ma et al. (2011). TTX affected
the upstroke phase, reducing the AP Vmax and delaying the AP
Peak. NIFED, by acting on ICaL, reduced the Ca
2+ influx through
the cell membrane thus reducing the AP duration. Conversely,
E4031 reduced the K+ eﬄux through the cell membrane, thus
prolonging the AP. Finally, CHR showed little effect on the AP
biomarkers, in agreement with the experiments.
Delayed Afterdepolarizations
In Figure 6 we compared the behavior of the Paci2013 and
the Paci2018 models in conditions of high extracellular Ca2+
concentration (Cao = 3.945mM instead of 1.8mM) and no
external stimulation, i.e., both models produced spontaneous
APs. As shown in Figure 6B, for t = [14, 30] s Irel underwent
a small reactivation, slowing down the decay of the Ca2+
transients (Figure 6E), affecting the inward component of
INaCa (Figure 6D) and triggering DADs in the membrane
potential (Figures 6A,F). Around t = 30 s, Irel underwent a
full reactivation, triggering an anticipated Ca2+ transient, which
resulted in a full anticipated beat (Volders et al., 2000). We
reported the extended AP and Ca2+ transient traces in the
Supplementary Figure 1. Conversely, the old Paci2013 model
did not show anomalies in the membrane potential (Figure 6G)
or Ca2+ transients (Figure 6J) as consequence of the high
extracellular Ca2+ concentration, while the Ca2+ in SR grew
dramatically. The improvements introduced in the Paci2018
model allowed to simulate DADs not only in case of Ca2+
FIGURE 1 | Comparison between the APs and Ca2+ transients simulated by
the new Paci2018 model (solid blue) and the Paci2013 model (dashed red).
(A) membrane potential. (B) Ca2+ transient.
overload, but offered flexibility to simulate behaviors such as
the spontaneous premature Ca2+ releases reported by Kim et al.
(2015) in their Figures 2C, 4B and their Supplemental Figure S1B.
We tested also the effect of a rate increment on the generation
of DADs in case of hypercalcemia, by providing external pacing.
In Supplementary Figure 2, we paced the Paci2018 model at its
spontaneous basal rate (38 bpm, in solid blue) and at a basal rate
increased by 50% (57 bpm, in dashed red). Despite the shorter
diastolic depolarization phase, also at 57 bpm we obtained a fully
developed DAD.
Figure 7 shows the spontaneous APs, Ca2+ transients and
INaCa, together with the release Ca
2+ flux (Irel), characterized
with premature Ca2+ releases. These traces were obtained with
a normal extracellular Ca2+ concentration (Cao = 1.8mM) but
simulatingmore “immature” RyRmachinery (namely, by shifting
RyRo,half and RyRc,half by −0.002 and 0.002mM respectively,
doubling RyRo time constant and reducing to half of its
nominal value RyRc time constant). In these conditions of more
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FIGURE 2 | Illustrative experimental Ca2+ transients from four cells (blue, cyan, green, magenta) and the Ca2+ transient simulated by the Paci2018 model (black).
The y-axis of the experimental traces (originally 1F/F) was normalized between the minimum and maximum values of the simulated trace for comparison. The inset
contains only the decay part (from 90 to 10% of the transient amplitude) of the experimental and simulated transients reported in the main Figure.
“immature” RyR machinery, we tested also the effects of INaCa
block on DADs generation. In Supplementary Figure 3, we tested
three INaCa block levels (50, 70, and 90%) while pacing the
Paci2018 model at 1Hz. With no INaCa block (solid blue trace),
APs show small DADs comparable to those reported in Figure 7
in t = [10, 25] s. By blocking 50% of INaCa (dashed orange trace),
we observed that the amplitude of DADs increases. Finally, for
the higher block levels, we did not observe any DAD.
Comparison With Other Experimental Data
In order to compare the Paci2018 model with the experimental
data, we challenged our model in the following conditions: (i) If
block by ivabradine, (ii) hyperkalemia, (iii) hypocalcemia.
We simulated If block by 3µM ivabradine as a 41% block of
If maximum conductance (Yaniv et al., 2012; Koivumäki et al.,
2018). As shown in Figure 8, If block induced only a slight
reduction of the frequency of spontaneous APs (−2.3%), in
agreement with (Kim et al., 2015), where 3µM had virtually no
effects on the spontaneous activity.
Kim et al. (2015) reported a slowdown of the spontaneous
activity in conditions of hyperkalemia (from 4 to 8mM the
median frequency dropped from about 1.2 to 0.2Hz) and
a further increase in extracelluar K+ to 12mM stopped the
spontaneous activity. Our single cell model showed a similar
trend (although with less sensitivity on K+): for Ko = 8mM
and Ko = 16mM the Ca
2+ transient spontaneous rate dropped
by 11% and 15% respectively. An extracellular K+ concentration
equal to 20mM stopped the hiPSC-CM spontaneous activity as
in Kim et al. (2015).
In the previous section, we tested the model in hypercalcemia
conditions to simulate Ca2+ overload and the generation of
DADs. We also challenged the model with an extracellular
Ca2+ concentration of 0.1mM (hypocalcemia) as in Kim et al.
(2015): again we observed a trend qualitatively in agreement with
the experimental data, since the rate of the spontaneous Ca2+
transients dropped by 17%.
DISCUSSION
In this paper we present an updated version of the Paci2013
model of ventricular-like hiPSC-CM (Paci et al., 2013), here
named Paci2018, developed by exploiting new Ca2+ transients
data and an automatic algorithm for the parameter optimization.
The Paci2018 model aims to overcome an important
limitation of the Paci2013 model, i.e., the simple formulation
of the Ca2+ release from SR, Irel, initially presented by
the TenTusscher2004 model of human adult ventricular
cardiomyocyte (ten Tusscher et al., 2004). The peculiarity of
such Irel is the direct link between the activation of ICaL and
the activation of Irel (through the voltage-dependent activation
gating variable d). This Irel formulation was then chosen for
its simplicity instead of more complex formulations, however
it presumes Irel to be directly dependent on the intracellular
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FIGURE 3 | Simulated spontaneous action potentials and ionic currents. (A,G) membrane potential. (B) Fast Na+ current (INa). (C) L-type Ca
2+ current (ICaL ). (D)
Funny current (If ) and Late Na
+ current (INaL ). (E) Transient outward K
+ current (Ito) and Na
+/K+ pump (INaK ). (F) Rapid delayed (IKr), slow delayed (IKs) and inward
(IK1) rectifier K
+ currents. (H) Na+/Ca2+ exchanger (INaCa). (I) Release current from sarcoplasmic reticulum (Irel). (J) Na
+ cytosolic concentration (Nai). (K) Cytosolic
Ca2+ concentration (Cai). (L) Sarcoplasmic Ca
2+ concentration (CaSR).
Ca2+ concentration and it prevents the model to be able to
reproduce Ca2+-related anomalies such as DADs. As reported
in Fink et al. (2011), models where the open probability of the
RyR-sensitive channels is directly dependent on the opening of
ICaL are unable to produce DADs. Indeed, DADs start from a
repolarized membrane, at potentials where the ICaL gates are
closed. Therefore, RyR-sensitive channels have to be able to
open even when ICaL is zero, which is not possible in the old Irel
formulation. Moreover, the presence of the crel constant in the
TenTussher2004 Irel formulation could allow a Ca
2+ flux also
from an empty SR, which is clearly not possible.
We chose a quite simple Irel formulation, inspired by the
Koivumäki2011 model of human adult atrial cardiomyocyte
(Koivumäki et al., 2011), characterized by three gating variables.
We did not choose more complex formulations, such as the
Markov formulation in TenTusscher2006 model (ten Tusscher
and Panfilov, 2006), since the latter was implemented mainly
to correctly take into account the presence of T-tubules and
the associated microdomains in the human adult ventricular
cell. However, hiPSC-CMs produced so far with current
differentiation protocols have not shown functional T-tubules (Li
et al., 2013).
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FIGURE 4 | Details on the new formulation of the Ca2+ release from
sarcoplasmic reticulum. (A) Time-course of the three sarcoplasmic release
current gates during spontaneous action potentials. (B) Ca2+ transients
during spontaneous action potentials.
In order to keep the Paci2018 model the most consistent with
its predecessor and with the Ma et al. dataset (Ma et al., 2011)
of ionic currents and AP biomarkers, we did not change the
formulation of INa, ICaL, If, Ito, IKr, IKs, and IK1, which were
carefully fitted for the development of the Paci2013 model. In
order to tune the Paci2018 model on the new data of Ca2+
transients, we decided to act only on those parameters defining
the formulation of currents for which the Ma et al. (2011) dataset
did not provide direct experimental data.
The result is a new model where spontaneous APs match the
Ma et al. dataset and where Ca2+ transients are in agreement with
the new Ca2+ dataset. In this paper, we did not aim to propose
only modifications to a previous model in order to simulate
a specific phenomenon of interest, but we wanted to develop
a new cardiac cell model to substantially increase modeling
accuracy. Therefore, it was fundamental to check the Paci2018
model capability to reproduce all the experimental data used for
the Paci2013 model validation. In detail, we tested the Paci2018
TABLE 3 | Quantitative effects of current blockers on stimulated APs.
AP features Experiments Simulations
Paci2013 Paci2018
Vmax TTX 3µM 41.2 ± 11.2% 18% GNa 26.2% 25.2%
TTX 10µM 16.7 ± 1.8% 6% GNa 23.5% 22.9%
TTX 30µM 16.8 ± 2.0% 2% GNa 20.7% 19.4%
APD50 E4031 30 nM 109.1 ± 3.7% 77% GKr 124.8% 124.9%
E4031 100 nM 113.4 ± 3.9% 50% GKr 160.0% 175.1%
APD90 E4031 30 nM 140.3 ± 7.6% 77% GKr 123.0% 123.4%
E4031 100 nM 170.4 ± 13.6% 50% GKr 151.4% 171.6%
APD50 Nifed 3 nM 84.6 ± 2.4% 93% GCaL 94.0% 95.3%
Nifed 10 nM 70.3 ± 6.1% 79% GCaL 76.5% 85.2%
Nifed 30 nM 65.7 ± 3.0% 56% GCaL 54.9% 65.3%
Nifed 100 nM 45.4 ± 4.5% 28% GCaL 33.5% 37.7%
APD90 Nifed 3 nM 89.4 ± 1.0% 93% GCaL 96.5% 95.9%
Nifed 10 nM 78.4 ± 4.4% 79% GCaL 84.3% 86.2%
Nifed 30 nM 74.0 ± 2.3% 56% GCaL 68.8% 67.7%
Nifed 100 nM 58.2 ± 5.4% 28% GCaL 51.4% 42.6%
The experimental significant effects (p < 0.05) of current blockers on stimulated hiPSC-
CMs from Ma et al. (2011) are compared with our previous model (Paci2013) and the
current one (Paci2018). Experiments were performed on hiPSC-CMs paced at 1Hz and
are reported in terms of mean± SE. Both experimental and simulated values are reported
as percent of the control values. For direct comparison, the block levels simulated by the
Paci2018 model were computed as in Paci et al. (2013) by means of dose-response
curves: TTX (IC50 = 0.64µM), Nifed (IC50 = 0.038µM) and E4031 (IC50 = 100 nM).
model’s responses to the same prototypical current blockers
used to validate the Paci2013 model, showing that the behavior
of the two models is consistent and in agreement with the
experimental data. We further validated the model to simulate
the experimentally observed phenomenon of DADs and other
specific results obtained in different experimental conditions,
being able to replicate all these experiments. In particular, the
Paci2018 model can reproduce Ca2+-related abnormalities such
as DAD-like anomalies that were not available in old formalism.
We observed that the small or full Irel reactivations increase
the cytosolic Ca2+ concentration and this produces an increased
activity of the inward component of INaCa, which then translates
in DAD-like abnormalities in the membrane potential. This is
particularly clear in Supplementary Figure 3, where for high
levels of INaCa block (70 and 90%) we do not observe DADs. It
is interesting to note that the 50% block is not enough to cancel
DADs: in fact, the inward INaCa component is still strong enough
and further enhanced by the cytosolic Ca2+ accumulation, due
to the very same INaCa block (minimum diastolic Ca
2+: 0.028
vs. 0.017µM; average diastolic Ca2+: 0.060 vs. 0.027µM, in
case of 50% INaCa block or no INaCa block, respectively). This
results in even larger DADs than in the no block case. Similar
DAD-like abnormalities in the electrical properties of hiPSC-
CMs were also observed in mutant hiPSC lines, such as those
derived from patients with HCM (Ojala et al., 2016) or CPVT
(Kujala et al., 2012). Of note, in this paper we do not aim
to simulate these mutations, which would deserve a specific
analysis by their own, but to provide a model which can enable
there in silico modeling. Notably, the membrane potential and
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FIGURE 5 | Simulation of current block effects on hiPSC-CMs paced at 1Hz. (A) Tetrodotoxine blocks INa, slowing down the upstroke phase. (B) Nifedipine blocks
ICaL, shortening APD and triangulating AP profile. (C) E4031 blocks selectively IKr, increasing APD. (D) IKs block by 3R4S-Chromanol 293B does not affect
significantly the AP shape.
cytosolic Ca2+ time-courses obtained by our model are very
similar to the experimental ones, as seen by comparison of
our Figures 6, 7 with Figures 2C, 4B and S1 in Kim et al.
(2015). In particular, Figure 4B in Kim et al. (2015) shows the
effect of isoproterenol, a non-selective β adrenoreceptor agonist,
which first induces small delayed spontaneous Ca2+ releases and
then triggers repetitive high rate firing. In our Figures 6A,E we
show a very similar pattern in conditions of hypercalcemia (see
Supplementary Figure 1 for an expanded version of Ca2+ and
AP time-courses), where the spontaneous Ca2+ releases, which
trigger DADs, finally cause a transition to a higher rate of Ca2+
transients and APs.
To further validate our model, we challenged it to simulate
specific conditions such as hyperkalemia and hypocalcemia, to
compare its behavior to published experimental data. The model
showed qualitative agreement with such experiments, in spite of
the fact that the spontaneous rate reduction is stronger in the
experiments. However, such differences can emerge from (i) the
multicellular embryoid body culturing and measurements, i.e.,
on multicellular ensembles, and especially (ii) as consequence of
the high inter-cell line and inter-laboratory variability showed
by hiPSC-CMs (Knollmann, 2013), especially in beating rate
and MDP. In fact, the embryoid bodies examined by Kim et al.
(2015) exhibited negligible IK1 and a much depolarized MDP
(−59.1 ± 3.3mV), which facilitate the spontaneous electrical
activity, as shown also by the high frequency of the spontaneous
Ca2+ transients (1Hz or higher) in control conditions. On
the contrary, the experimental datasets we used in this paper
showed slower spontaneous activity and more hyperpolarized
MDP, as simulated by our model and reported in Table 2
(MDP=−75.8mV, FREQ= 0.65Hz).
We tested also the capability of the Paci2018model to simulate
early afterdepolarizations (EADs) in conditions of IKr block: the
protocol and the results of the EAD simulations were reported in
section 3 of the Supplementary Material. We observed that the
Paci2018, as the old Paci2013 model, does not produce EADs.
This is not surprising, since we designed the Paci2018 model
carefully maintaining the same formulation for the ion currents
that we fit on the experimental data by Ma et al. (2011), and
that we used for the Paci2013 model (Paci et al., 2013). However,
in our previous study (Paci et al., 2016), we demonstrated that
IKr block triggered EADs in a population of in silico hiPSC-
CM based on the Paci2013 model. Replicating here that study
is out of the scope of this paper, however we decided to test if
two parameter sets, which in Paci et al. (2016) triggered EADs,
and one parameter set, which triggered repolarization failure,
could induce repolarization abnormalities also in the Paci2018
model. Supplementary Figure 4 shows that, as expected, two
derived models produced EADs and the third one repolarization
failure. In particular, as reported in the Supplementary Table 1,
these parameter sets showed (compared to baseline): (i) greater
ICaL (which corresponds to a greater Ca
2+ influx during the
repolarization phase in case of ICaL reactivation); (ii) greater
INaCa (which is inward during repolarization, thus promoting
abnormalities in conditions of compromised repolarization as
in case of IKr block), and (iii) smaller IK1 (corresponding to a
smaller contribution to the membrane potential stabilization).
It is also interesting to notice that the three parameter sets
showed greater IKr compared to baseline: this suggests that in
models where IKr is highly expressed, a 90% block can have more
dramatic effects than in cells expressing smaller IKr. This small
test suggests, as we reported among the limitations, that the use
of more refinedmodeling approaches, e.g., populations of in silico
models, is advisable to simulate specific phenomena (in this case
EADs as consequence of IKr block) in cell types characterized by
high electrophysiological variability. In the perspective of offering
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FIGURE 6 | Comparison of the behavior of the Paci2018 (in blue, A–F) and the Paci2013 model (in red, G–K) in case of spontaneous APs and Ca2+ overload induced
by hypercalcemia (Cao = 3.945mM). In this condition both models can produce spontaneous APs, reported in (A,G). The Paci2018 model shows a saturation of the
sarcoplasmic Ca2+ concentration (C), after which reactivation of Irel (B) induces a distortion in the shape of the Ca
2+ transients (E) and in the inward component of
INaCa (D), which corresponds to DADs in the membrane potential (A,F) in between t = [14, 30] s. At t = 30 s a strong spontaneous release of Ca
2+ from SR is
shown, which induces a spurious AP. On the contrary, the Paci2013 is not affected in these conditions and does not produce repolarization abnormalities (G).
researchers a tool to investigate the mechanisms of ventricular
arrhythmia development in hiPSC-CMs, we ran also two
preliminary tests about the occurrence of alternans or alternans-
like patterns in the Paci2018 model (Methods and Results are
detailed in section 4 of the Supplementary Material). When
pacing the Paci2018 model at 120 bpm (2Hz), the membrane
potential exhibited an alternans-like pattern, characterized by a
full AP followed by a smaller one (Supplementary Figure 5A).
We tested also the effect of very high pacing rate (200 bpm,
3.33Hz) in ischemia-like conditions (Supplementary Figure 5B):
in this case, the membrane potential was strongly depolarized
(−60mV) and exhibited 2:1 alternans. We consider these results
valuable also for more advanced studies regarding arrhythmias
propagation in case of extension of the simulations to a
monodimensional strand or a bidimensional patch.
Overall, we believe that the here presented Paci2018 model
substantially increases hiPSC-CM modeling accuracy. Of course,
as every in silico model, also the Paci2018 is an approximated
description of a real system: consequently, new mechanisms
can be explored and improved. This is especially true for such
a complex cellular system as hiPSC-CM, which is not fully
characterized yet. The main limitation that affects the Paci2018
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FIGURE 7 | Repolarization abnormalities with standard extracellular Ca2+
concentrations. Such behavior was obtained with a control extracellular Ca2+
concentration Cao = 1.8mM, shifting RyRo,half and RyRc,half by −0.002 and
0.002mM respectively, doubling RyRo time constant and reducing to half of its
nominal value RyRc time constant. These traces show the ability of the
Paci2018 to simulate pathological conditions affecting the Ca2+ from SR. (A)
Membrane potential. (B) INaCa. (C) Cytosolic Ca
2+ concentration. (D) Irel. A
similar morphology of the cytosolic Ca2+ time-course is reported in Kim et al.
(2015) in their Figure 4B.
FIGURE 8 | Effect of 3µM ivabradine on the spontaneous APs. Administration
of ivabradine (in dashed red) slightly slows down the rate of the spontaneous
APs in comparison to control (in solid blue).
model, as well the other single cell in silico models available in
literature, is the fact that the simulated behavior belongs to a
theoretical cell, built on averaged experimental data from many
cells. In spite of our efforts to build the Paci2018 in a rigorous
way, we do not have the presumption to consider it representative
of all the hiPSC-CMs available nowadays, both from commercial
lines and laboratory-specific lines. This is particularly true in case
of an in vitromodel like hiPSC-CMs, since the same experiments
that we need to build an in silico model are extremely variable,
as reported by multiple studies (Knollmann, 2013; Lu et al.,
2015; Paci et al., 2017). As an additional example, in Lu et al.
(2015) the authors succeeded in culturing iCell hiPSC-CMs that
showed limited biomarker variability. Nevertheless, their cells
showed way slower spontaneous beating rate than the cells we
used to build our model (∼15 bpm vs. ∼38 bpm), despite both
datasets were recorded at the same 37◦C temperature. In order
to have a better translation from in silico to in vitro models
and finally to (pre)clinical applications, more refined modeling
techniques exist, e.g., the population of in silico models (Britton
et al., 2013; Passini et al., 2017). In addition to this, in terms
of translation of drug test results from hiPSC-CMs to clinical
applications, more challenges emerged recently. For example, in
Abi-Gerges et al. (2017), testing a panel of 30 drugs on non-
paced hiPSC-CMs provided on one hand good predictivity of
pro-arrhythmic events, but on the other hand limited predictivity
as an early QT screening. Therefore, in spite the high potential of
hiPSC-CMs as in vitro models for diseases and drug tests, direct
translation of results is still a work in progress, as indicated by
the fact that advances in phenotype selection, cell maturation
and combined recording platforms are currently being made.
One inherent limitation of the Paci2018 model consists in the
use of two different datasets of experimental data, one for the
AP and ionic current data and the other for Ca2+ data. This
is clear, e.g., by comparing the mean values of APD90 and
Ca2+ transient DURATION biomarkers: 414.7 and 804.5ms,
respectively. It is known that high affinity Ca2+ indicators,
such as Fluo-4, can artificially prolong the Ca2+ transients and
that Ca2+ transients last more than APs (Lee et al., 2012);
however, the aforementioned Ca2+ transient DURATION value
is substantially longer than APD90. Therefore, we tried to find
an acceptable tradeoff by means of the parameter optimization
algorithm, in order to fulfill all the experimental ranges of both
the AP and Ca2+ transient biomarkers. In particular, in the
cost function we chose heavier weights (wi = 2) only for two
critical biomarkers which characterize hiPSC-CMs, i.e., MDP
(depolarized compared to adult cardiomyocytes) and the rate
of the spontaneous APs. For all the other biomarkers, the
weights were set to one. The tradeoff obtained by the parameter
optimization produced a model that simulates Ca2+ transients
whose DURATION is 617.8ms. Despite this value lies within
the experimental range 804.5 ± 188.0ms, it is very close to its
lower bound. Conversely, the DT9010 biomarker properly lies
within its experimental range, although slightly smaller than
the experimental mean DT9010 (409.8 ± 100.1 vs. 367.6ms).
The inset included in Figure 2 shows only the decay part (from
90 to 10% of the transient amplitude) of the experimental
and simulated transients reported in the main Figure 2: our
simulated decay lies within the illustrative experimental traces,
as well as DT9010 of the simulated transient is included in the
experimental interval. Of note, the experimental traces reported
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in Figure 2 are purely illustrative of our experiments: the global
quantitative comparison between experiments and simulations
is done in Table 2 in terms of biomarkers. It is also known
that temperature affects the spontaneous electrical activity of
hiPSC-CMs, e.g., in Laurila et al. (2016) the authors showed
how the temperature increments and reductions accelerate or
slow down hiPSC-CM spontaneous beating, respectively. The
fact that the AP and Ca2+ transient experimental datasets, chosen
to develop the Paci2018 model, were recorded at the same
temperature (35–37◦C) further mitigates the differences between
the two datasets. Another potential limitation of our model is
related to its simple structure, consisting of two compartments
only (cytosol and SR). Such compartmentalization does not
allow to simulate a spatial inhomogeneous Ca2+ distribution,
as conversely recently done by others (Koivumäki et al., 2018).
We preferred to keep the model formulation simple, without
entering in such detailed description, since it would have required
a more complex mathematical formulation, a more detailed
knowledge of the subcellular organization of hiPSC-CMs and,
consequently, a more challenging parameter identification and
higher simulation time. However, our formulation is successful in
simulating the most important electrophysiological mechanisms
at the whole cell level, including DADs elicited from different
kind of stresses, without resorting to random RyR openings, as
done in Koivumäki et al. (2018). A final limitation of the Paci2018
model is that it describes only the electrophysiology and the Ca2+
handling, but it does not take into consideration contractility. In
literature, a few models of myofilament are available (Negroni
and Lascano, 2008; Rice et al., 2008; Negroni et al., 2015).
For instance, in Negroni et al. (2015) the authors presented
an integrated rabbit ventricular cardiomyocyte model, which
included also the mathematical description of force generation
and the myofilament Ca2+ kinetics. However, the sarcomeric
structure of hiPSC-CMs is immature and the myofibrils in
hiPSC-CMs are oriented in multiple directions within the cell:
in Bedada et al. (2016) a higher level of sarcomeric organization
was reached only by repopulating hiPSC-CMs into a biological
cardiac matrix. We acknowledge the potential of an integration
of the myofilament description in the Paci2018, nevertheless
the translation from a different species model of, e.g., rabbit
cardiomyoycte to a hiPSC-CM model is not elementary and out
of the scope of this paper. Future developments of this work will
include using the Paci2018 model to ran in silico drug tests and to
ran monodimensional and bidimensional simulations, as done,
e.g., by Raphel et al. with the Paci2013model (Raphel et al., 2017).
In conclusion, in this work we present an updated and
more versatile version of our hiPSC-CM in silico model,
based on a new dataset of electrophysiological data. Our
model can represents the basis for new in silico studies on
the effects of drugs or mutations (e.g., CPVT), which affect
the Ca2+ handling in hiPSC-CMs. Due to its relatively light
formulation (23 ordinary differential equations), our model is
suitable also for very large studies on in silico populations, e.g.,
to support screening of different drug/compounds at various
concentrations.
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